ELISA 3: Early vs. late invasive strategy in patients without high-risk ST elevation

The invasive strategy is preferred to treat patients with acute coronary syndromes without ST-segment elevation, but the ideal time for the procedure is controversial. This study randomized 542 patients with acute coronary syndrome without high-risk ST elevation to carry out immediate (invasive treatment within 12 hours) or late treatment (after 48 hours). The primary endpoint<a href="https://solaci.org/en/2015/06/24/elisa-3-early-vs-late-invasive-strategy-in-patients-without-high-risk-st-elevation/" title="Read more" >...</a>

ORBIT II: new atherectomy device

The objective of the study was to test the use of a new atherectomy device to prepare severely calcified lesions. It was an observational, prospective, multicenter study that included 443 patients from 49 sites with a 30-day follow-up. The lesion was classified as severely calcified, as fluoroscopy showed the presence of calcium on both sides<a href="https://solaci.org/en/2015/06/24/orbit-ii-new-atherectomy-device/" title="Read more" >...</a>

J- REVERSE: sirolimus-eluting vs. everolimus-eluting stent in bifurcation lesions

Asymmetrical expansion of the stent produces an uneven neointimal growth and increases the risk of thrombosis. The study was divided into two parts: the first one aimed at comparing, in the acute phase and the medium term, the result of provisional bifurcation stenting technique with sirolimus-eluting stent vs everolimus-eluting stent (both guided by IVUS); the<a href="https://solaci.org/en/2015/06/24/j-reverse-sirolimus-eluting-vs-everolimus-eluting-stent-in-bifurcation-lesions/" title="Read more" >...</a>

EUROMAX: Bivalirudin during transport to primary angioplasty

The HORIZONS AMI trial showed the usefulness of bivalirudin in reducing mortality and bleeding compared with the use of heparin plus glycoprotein IIBIIIA. However, some questions remained unanswered: What is the utility of starting the infusion during the ambulance journey? Is it possible to reduce the risk of acute thrombosis by extending bivalirudin infusion or<a href="https://solaci.org/en/2015/06/24/euromax-bivalirudin-during-transport-to-primary-angioplasty/" title="Read more" >...</a>

SAVOR-TIMI 53: Saxagliptin showed no cardiovascular benefit

The cardiovascular safety and efficacy of some hypoglycemic including saxagliptin (Onglyza), an inhibitor of dipeptidyl peptidase 4 (DPP-4), is not well established. 16492 patients were randomized diagnosed with type 2 diabetes with a history of cardiovascular events or high risk to receive saxagliptin or placebo. Other medications for diabetes, including hypoglycemic, were permitted. The combined<a href="https://solaci.org/en/2015/06/24/savor-timi-53-saxagliptin-showed-no-cardiovascular-benefit/" title="Read more" >...</a>

Current hemodialysis patients show similar results for sirolimus-eluting and paclitaxel

Original title: Drug-eluting stents in patients on chronic haemodialysis: Paclitaxel-eluting stents vs. limus –eluting stents Reference: Gabriel l. Sardi, et al. Cardiovasc Revasc Med. 2014 Mar;15(2):86-91. End Stage Renal Disease (ESRD) including renal failure on hemodialysis is associated with coronary heart disease and diabetes with subsequent need for revascularization that in this special population has a high<a href="https://solaci.org/en/2015/06/01/current-hemodialysis-patients-show-similar-results-for-sirolimus-eluting-and-paclitaxel/" title="Read more" >...</a>

The ambulance is the best way to get to the hospital in case of an infraction

Only 16 per cent of patients suffering a myocardial infarction call 911 for help, stated the experts of the Semicyuc: the Spanish Medical Society of ICU (Sociedad Española de Medicina Intensiva y Unidades Coronarias), at the ARIAM study presentation. This study branched out of a three month registry of 2,051 MI patients. From these data<a href="https://solaci.org/en/2015/06/01/the-ambulance-is-the-best-way-to-get-to-the-hospital-in-case-of-an-infraction/" title="Read more" >...</a>

TOTAL Trial: The Best on Manual Thrombectomy in AMI Patients

Original title: Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. Reference: S.S. Jolly et al. for the TOTAL Investigators. N Engl J Med. 2015 Apr 9;372(15):1389-98. Manual thrombectomy is a routine procedure with ST elevation AMI patients. This common practice proved to reduce mortality in the TAPAS study. However, the TASTE study did not observe<a href="https://solaci.org/en/2015/05/20/total-trial-the-best-on-manual-thrombectomy-in-ami-patients/" title="Read more" >...</a>

CTO revascularization is beneficial

Título original: Long-Term Survival Benefit of Revascularization Compared UIT Medical Therapy in Practice UIT Coronary Chronic Total Occlusion and Well-Developed Collateral Circulation. Reference: Woo Jin Jan, el at. J Am Coll Cardiol Interv 2015;8:271-9 Multiple studies have shown the benefit of chronic total occlusion (CTO) revascularization, but for patients presenting Rentrop 3 grade collateral circulation (CC), such benefit<a href="https://solaci.org/en/2015/03/24/cto-revascularization-is-beneficial/" title="Read more" >...</a>

The MGuard stent shows a trend toward reduced mortality in PCI

Original title: Mesh-Covered Embolic Protection Stent Implantation in ST-Segment–Elevation Myocardial Infarction. Final 1-Year Clinical and Angiographic Results From the MGUARD for Acute ST Elevation Reperfusion Trial. Reference: DariuszDudek et al. CircCardiovascInterv. 2015 Feb;8(2).   The MGuard is a micronet mesh-covered stent designed to reduce distal embolization in the context of ST elevation myocardial infarction. In the MASTER study<a href="https://solaci.org/en/2015/02/23/the-mguard-stent-shows-a-trend-toward-reduced-mortality-in-pci/" title="Read more" >...</a>

acute myocardial infarction